Naveen Pemmaraju1, Michael A Thompson1, Ruben A Mesa1, Tejas Desai1. 1. The University of Texas MD Anderson Cancer Center, Houston, TX; Aurora Research Institute, Aurora Health Care, Milwaukee, WI; Mayo Clinic, Scottsdale AZ; US Department of Veterans Affairs; and Nephrology On-Demand Analytics, Charlotte, NC.
Abstract
PURPOSE: The use of social media, in particular Twitter, has substantially increased among health care stakeholders in the field of hematology and oncology, with an especially sharp increase in the use of Twitter during times of major national meetings. The most attended meeting in the oncology field is the ASCO annual meeting. Little is known about the detailed metrics involved in the use, volume, and impact of Twitter during the ASCO annual meeting. METHODS: We conducted a retrospective review of tweets during the ASCO annual meetings from 2011 to 2016. The total data set encompassed 190,732 tweets from 39,745 authors over six consecutive ASCO meetings from 2011 to 2016 (inclusive). Tweets, all publically available, were collected by Nephrology On-Demand Analytics. RESULTS: The number of individual authors increased from 1,429 during the 2011 ASCO meeting to 15,796 during the 2016 ASCO meeting, an 11-fold increase over the total 5-year period. There was a notable increase in tweets from the 2011 ASCO meeting (n = 7,746) to the 2016 ASCO meeting (n = 72,698), a nine-fold increase during the study period. The most commonly tweeted term or topic changed over time, generally reflecting the breakthroughs of each designated year; these terms were "melanoma" for both the 2011 and 2012 ASCO meetings; "breast cancer" for the 2013 ASCO meeting; "lung cancer" for the 2014 ASCO meeting; and "ImmunOnc" or "immunotherapy/immuno-oncology" for both the 2015 and 2016 ASCO meetings. CONCLUSION: The use of Twitter among health care stakeholders during the ASCO meeting has markedly increased over time, demonstrating the increasing role of social media in the dissemination of findings at the most highly attended hematology and oncology conference of the year.
PURPOSE: The use of social media, in particular Twitter, has substantially increased among health care stakeholders in the field of hematology and oncology, with an especially sharp increase in the use of Twitter during times of major national meetings. The most attended meeting in the oncology field is the ASCO annual meeting. Little is known about the detailed metrics involved in the use, volume, and impact of Twitter during the ASCO annual meeting. METHODS: We conducted a retrospective review of tweets during the ASCO annual meetings from 2011 to 2016. The total data set encompassed 190,732 tweets from 39,745 authors over six consecutive ASCO meetings from 2011 to 2016 (inclusive). Tweets, all publically available, were collected by Nephrology On-Demand Analytics. RESULTS: The number of individual authors increased from 1,429 during the 2011 ASCO meeting to 15,796 during the 2016 ASCO meeting, an 11-fold increase over the total 5-year period. There was a notable increase in tweets from the 2011 ASCO meeting (n = 7,746) to the 2016 ASCO meeting (n = 72,698), a nine-fold increase during the study period. The most commonly tweeted term or topic changed over time, generally reflecting the breakthroughs of each designated year; these terms were "melanoma" for both the 2011 and 2012 ASCO meetings; "breast cancer" for the 2013 ASCO meeting; "lung cancer" for the 2014 ASCO meeting; and "ImmunOnc" or "immunotherapy/immuno-oncology" for both the 2015 and 2016 ASCO meetings. CONCLUSION: The use of Twitter among health care stakeholders during the ASCO meeting has markedly increased over time, demonstrating the increasing role of social media in the dissemination of findings at the most highly attended hematology and oncology conference of the year.
Authors: Hendrik Borgmann; Stacy Loeb; Johannes Salem; Christian Thomas; Axel Haferkamp; Declan G Murphy; Igor Tsaur Journal: Urol Oncol Date: 2016-03-29 Impact factor: 3.498
Authors: Deanna J Attai; Michael S Cowher; Mohammed Al-Hamadani; Jody M Schoger; Alicia C Staley; Jeffrey Landercasper Journal: J Med Internet Res Date: 2015-07-30 Impact factor: 5.428
Authors: Jason B Colditz; Kar-Hai Chu; Sherry L Emery; Chandler R Larkin; A Everette James; Joel Welling; Brian A Primack Journal: Am J Public Health Date: 2018-06-21 Impact factor: 9.308
Authors: Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane Journal: Curr Hematol Malig Rep Date: 2017-12 Impact factor: 3.952
Authors: Mina S Sedrak; Meghan M Salgia; Cristiane Decat Bergerot; Kemi Ashing-Giwa; Brendan N Cotta; Jacob J Adashek; Nazli Dizman; Andrew R Wong; Sumanta K Pal; Paulo Gustavo Bergerot Journal: JCO Clin Cancer Inform Date: 2019-03
Authors: Nayeli A Martinez-Ibarra; Yuly A Remolina-Bonilla; Hector H Buerba-Vieregge; Regina Barragan-Carrillo; Francisco J Castro-Alonso; Samantha Mateos-Corella; Maria T Bourlon Journal: Front Endocrinol (Lausanne) Date: 2022-06-29 Impact factor: 6.055
Authors: Deanna J Attai; Patricia F Anderson; Michael J Fisch; David L Graham; Matthew S Katz; Jennifer Kesselheim; Merry Jennifer Markham; Nathan A Pennell; Mina S Sedrak; Michael A Thompson; Audun Utengen; Don S Dizon Journal: Semin Hematol Date: 2017-08-12 Impact factor: 3.851
Authors: Naveen Pemmaraju; Audun Utengen; Vikas Gupta; Michael A Thompson; Andrew A Lane Journal: Curr Hematol Malig Rep Date: 2018-12 Impact factor: 3.952
Authors: Sara Beltrán Ponce; Maura M Barry; Don S Dizon; Matthew S Katz; Martina Murphy; Eleonora Teplinsky; Stacey Tinianov; Deanna J Attai; Merry Jennifer Markham Journal: Future Oncol Date: 2022-02-03 Impact factor: 3.674